Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
Rhea-AI Summary
Sunshine Biopharma (NASDAQ:SBFM) announced that Health Canada has approved its generic Ondansetron 4mg and 8mg tablets, including standard film-coated and Oral Disintegrating Tablet (ODT) forms, for the Canadian market. Ondansetron is the generic equivalent of Zofran® and is prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery.
According to Sunshine Biopharma, the launch expands its portfolio into chemotherapy‑related nausea and vomiting, leveraging its Canadian distribution network via subsidiary Nora Pharma. The company expects Ondansetron to be ready for shipment to pharmacies by the end of 2026 and currently markets 60 generic drugs in Canada, with about 12 more scheduled for launch in 2026.
Positive
- Health Canada approval for 4mg and 8mg Ondansetron tablets, including ODT
- Strategic expansion into nausea and vomiting from cancer therapy segment
- Established Canadian distribution via wholly owned subsidiary Nora Pharma
- Portfolio scale: 60 generic drugs currently on Canadian market
- Planned launches: approximately 12 additional generic drugs in 2026
- Targets growing global nausea medicine market projected at $4.86 billion by 2032
Negative
- None.
News Market Reaction – SBFM
In the Jul 28 session, SBFM declined 6.54%, reflecting a notable negative market reaction. Argus tracked a trough of -24.5% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 20 | Research publication | Positive | -3.9% | Peer-reviewed PLpro inhibitor research showed activity across variants and efficacy in a mouse model. |
| Jun 25 | Canadian drug approval | Positive | +4.9% | Canadian approval covered generic anastrozole tablets distributed through Nora Pharma before year-end shipping. |
| Jun 01 | Canadian drug approval | Positive | -5.9% | Canadian approval covered generic rivaroxaban tablets with planned October 2026 shipping. |
| May 29 | Patent issuance | Positive | -19.8% | U.S. patent covered PLpro inhibitors advancing toward GLP studies before clinical trials. |
| May 28 | Reverse stock split | Neutral | -25.3% | Reverse split targeted Nasdaq minimum bid-price compliance and reduced outstanding shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history showed negative 24-hour reactions for four of five events, while the June 25 Canadian approval was followed by a positive 4.9% reaction.
Key Terms
5-ht3 receptor antagonist medical
oral disintegrating tablets medical
cagr financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Ondansetron tablets of 4mg and 8mg for the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran®.
Ondansetron is highly prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by blocking the actions of chemicals in the body that trigger nausea and vomiting. By offering both standard film-coated tablets and Oral Disintegrating Tablets (Ondansetron ODT), healthcare providers can better tailor the treatment to individual patient needs and physical condition.
According to Coherent Market Insights, the global Nausea Medicine Market is estimated to be valued at
Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma Inc. The addition of Ondansetron to our portfolio of drugs represents a strategic expansion for the Company into the area of nausea and vomiting caused by cancer therapy. The Company anticipates that its Ondansetron will be ready to ship to pharmacies by the end of 2026.
"We are pleased to introduce Ondansetron oral tablets and Ondansetron ODT as the newest addition to our expanding portfolio of high-quality generic drugs," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This approval strengthens our position in the generics market and reflects our ongoing commitment to delivering affordable medicines that patients and healthcare providers can rely on."
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire